#USA #Boston #Pillar Biosciences #NGS #Oncology Diagnostics

Pillar Biosciences to Showcase NGS Innovations at AMP 2025

Pillar Biosciences, Inc., a leader in Decision Medicine™, has announced plans to participate in the upcoming 2025 Association for Molecular Pathology (AMP) Annual Meeting, set to take place in Boston, MA. This event, renowned for its focus on molecular pathology advancements, will serve as a platform for Pillar and its scientific partners to present significant research findings, highlighting eight innovative studies and hosting three workshops.

In a statement about the company's participation, Dan Harma, the Chief Commercial Officer, underscored the commitment of Pillar Biosciences to enhancing precision oncology through rapid and efficient next-generation sequencing (NGS) technologies. “The data being shared at AMP 2025 highlights our strong commitment to advancing precision oncology through rapid and accurate NGS,” he remarked. He further emphasized the role of these technologies in making genomic testing more accessible for laboratories and healthcare providers globally, facilitating better patient care through informed treatment decisions.

Highlights of Pillar's Participation at AMP 2025

Corporate Workshops

On November 12, Pillar Biosciences will lead three workshops showcasing the practical applications of their technologies:
1. Rapid Detection of Actionable Biomarkers in Liquid Biopsy from Non-Small Cell Lung Cancer and Breast Cancer – Presented by Dr. Beatriz Bellosillo from Hospital del Mar and Ryan Demers from AstraZeneca. This workshop will focus on utilizing targeted NGS-based assays for quick biomarker detection to inform treatment strategies.
2. Validation of the oncoReveal® Myeloid Panel Using Illumina MiSeq i100 – Led by experts from the University of Pennsylvania Health System and Illumina, this session will highlight laboratory validation processes for rapid NGS in hematologic malignancies.
3. Accelerating Precision Medicine with Front-Line NGS – Dr. Mark Ewalt from Memorial Sloan Kettering Cancer Center will discuss the integration of rapid NGS technologies in enhancing precision medicine approaches.

Scientific Poster Presentations

In addition to workshops, Pillar Biosciences will present various scientific posters throughout the event, offering insights into their technological advancements:

• - Performance Comparison of Illumina MiSeq i100 with other established instruments.
• - Detecting Contamination in sequencing libraries using germline markers—a critical step in ensuring data accuracy.
• - Ultra-Low Frequency ESR1 Mutations detection utilizing the oncoReveal® Essential LBx Panel, which could significantly impact treatment protocols.
• - Performance Analysis of Targeted vs. Comprehensive NGS Panels in paired tumor and liquid biopsy samples.

About Pillar Biosciences

Pillar Biosciences is at the forefront of Decision Medicine™, employing highly accurate NGS testing technology to optimize precision therapies for cancer patients. Their solutions, such as the proprietary SLIMamp® and PiVAT® technologies, help streamline the testing process while cutting down on costs and improving the accessibility of vital testing. The company asserts that it has over 20 NGS testing kits available, spanning various applications and stages of development.

Located in Natick, Massachusetts, Pillar is committed to enhancing the clinical workflow for healthcare professionals and patients alike, ensuring that high-quality genomic data drives informed decision-making in oncology across the globe. For more information about their innovative products and services, interested parties can visit their official website at pillarbiosci.com.